Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB develops oncology-focused cell-based therapies (Cell-in-a-Box encapsulation) aligned with Biotech - Oncology.
|
$6.38M |
$0.93
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$6.35M |
$1.41
-3.10%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$6.22M |
$5.81
+0.87%
|
|
MODV
ModivCare Inc.
MODV delivers technology-enabled healthcare services (NEMT, PCS, Monitoring) and related care operations, aligning with Healthcare Services & Facilities.
|
$6.19M |
$0.43
|
|
MHUA
Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies' core business is the manufacturing and sale of disposable medical device consumables.
|
$6.08M |
$0.23
-1.39%
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$6.06M |
$0.82
+0.58%
|
|
BNGO
Bionano Genomics, Inc.
BNGO directly manufactures and sells diagnostic instrument hardware used for Optical Genome Mapping (OGM).
|
$6.06M |
$1.81
+0.56%
|
|
ICU
SeaStar Medical Holding Corporation
Core product is a blood purification device (SCD) used in critical care to modulate immune response and remove inflammatory mediators, fitting Blood Purification Devices.
|
$6.02M |
$0.57
+2.85%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$6.00M |
$1.86
-0.53%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$5.93M |
$0.35
-3.82%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$5.90M |
$1.93
-3.02%
|
|
HSCS
HeartSciences Inc.
HeartSciences develops medical devices (wavECG) and biometric sensing capabilities, aligning with Medical Devices & Biometrics.
|
$5.90M |
$3.02
-0.98%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$5.89M |
$5.05
+0.60%
|
|
LQMT
Liquidmetal Technologies, Inc.
Medical Device Components: Liquidmetal designs/manufactures customized components for medical devices using its amorphous alloys.
|
$5.87M |
$0.14
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$5.83M |
$1.06
-1.85%
|
|
NAKA
Kindly MD, Inc.
Provides patient-first healthcare services and operates clinics/delivery of care under KindlyMD.
|
$5.60M |
$0.91
-2.25%
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$5.57M |
$3.88
-0.77%
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$5.55M |
$1.37
+0.74%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.35M |
$1.65
+0.61%
|
|
BIXT
Bioxytran, Inc.
MDX Viewer is an FDA-approved diagnostic device that measures tissue oxygenation and provides real-time metabolic insights; a direct product/service Bioxytran provides.
|
$5.35M |
$0.07
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$5.31M |
$8.78
-1.63%
|
|
BTCY
Biotricity, Inc.
Core cardiology device portfolio including 3-channel ECG monitoring platforms (Bioflux/Biocore/Biocore Pro).
|
$5.28M |
$0.57
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$5.21M |
$3.39
+3.99%
|
|
SNGX
Soligenix, Inc.
HyBryte CTCL and related oncology assets position Soligenix in Biotech - Oncology.
|
$5.06M |
$1.55
+0.32%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$5.03M |
$0.78
+3.22%
|
|
SOBR
SOBR Safe, Inc.
SOBR directly manufactures biometric-enabled medical devices (SOBRcheck) and wearable monitoring hardware (SOBRsure) paired with a cloud software platform.
|
$4.91M |
$3.22
-0.62%
|
|
XWEL
XWELL, Inc.
XWEL's XpresTest program represents laboratory testing and advisory services, anchored by CDC collaborations and pathogen surveillance.
|
$4.65M |
$0.98
+4.38%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$4.62M |
$0.38
+7.76%
|
|
RMSL
REMSleep Holdings, Inc.
RMSL designs and manufactures CPAP-based respiratory medical devices (DeltaWave), directly aligning with 'Medical Devices & Biometrics'.
|
$4.53M |
$0.00
|
|
STSS
Sharps Technology, Inc.
Core product category: Safety syringes (SafeGard/Sologard) with passive safety features.
|
$4.49M |
$4.30
-2.49%
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$4.47M |
$0.03
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$4.43M |
$4.54
+1.22%
|
Showing page 36 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
